imatinib mesylate has been researched along with Genome Instability in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhatia, R; Bolton-Gillespie, E; Flis, S; Holyoake, TL; Hoser, G; Kerstiens, L; Klein, HU; Koptyra, M; Koschmieder, S; Lange, T; Maier, J; Modi, H; Müller, MC; Nieborowska-Skorska, M; Schemionek, M; Seferynska, I; Skorski, T; Stoklosa, T | 1 |
| Bolton-Gillespie, E; Cerny-Reiterer, S; Dasgupta, Y; Gornicka, B; Hantschel, O; Hoser, G; Kantekure, K; Koptyra, M; Müschen, M; Nieborowska-Skorska, M; Richardson, C; Roy, D; Skorski, T; Stoklosa, T; Valent, P; van der Kuip, H; Wasik, MA | 1 |
| Filipič, M; Gajski, G; Garaj-Vrhovac, V; Gerić, M; Novak, M; Nunić, J; Žegura, B | 1 |
| Goldman, JM; Melo, JV | 1 |
| Antolino, A; Consoli, C; Consoli, ML; Cupri, A; Del Fabro, V; Di Raimondo, F; Massimino, M; Stagno, F; Stella, S; Tambè, L; Vigneri, P | 1 |
| Skorski, T | 1 |
| Acosta, JC; Albajar, M; Bermúdez, A; Delgado, MD; Donato, N; Gómez-Casares, MT; León, J; Llorca, J; Mauleon, I; Vaqué, JP | 1 |
| Alimena, G; Breccia, M; Cannella, L; Colafigli, G; De Cuia, MR; Loglisci, G; Nanni, M; Salaroli, A; Serrao, A | 1 |
| Helgason, GV; Holyoake, TL; Karvela, M | 1 |
| Bhatia, R; Copland, M; Flis, K; Irvine, D; Skorski, T | 1 |
| Fabarius, A; Giehl, M; Haaß, W; Hofmann, WK; Nittka, S; Schrotz-King, P; Seifarth, W; Stehle, M | 1 |
| Ilaria, RL | 1 |
| Amiel, A; Fejgin, M; Gaber, E; Josef, G; Leopold, L; Lishner, M; Yukla, M | 1 |
| Eaves, A; Eaves, C; Jiang, X; Smith, C | 1 |
| Eaves, A; Eaves, C; Jiang, X; Saw, KM | 1 |
| Bosa, M; Cilloni, D; Rege-Cambrin, G; Saglio, G; Ulisciani, S | 1 |
5 review(s) available for imatinib mesylate and Genome Instability
| Article | Year |
|---|---|
BCR-ABL in chronic myelogenous leukemia--how does it work?
Topics: Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Genomic Instability; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2008 |
Genomic instability: The cause and effect of BCR/ABL tyrosine kinase.
Topics: Apoptosis; Benzamides; Cell Differentiation; Disease Progression; DNA Repair; Drug Resistance, Neoplasm; Enzyme Activation; Fusion Proteins, bcr-abl; Genomic Instability; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Genetic; Mutation; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Reactive Oxygen Species | 2007 |
Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Topics: Benzamides; Clinical Trials as Topic; Disease Management; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genomic Instability; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloid Cells; Piperazines; Pluripotent Stem Cells; Protein Kinase Inhibitors; Pyrimidines; Therapies, Investigational; Treatment Outcome | 2012 |
The challenges of targeting chronic myeloid leukemia stem cells.
Topics: ATP-Binding Cassette Transporters; Benzamides; Cell Differentiation; Fusion Proteins, bcr-abl; Genomic Instability; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Philadelphia Chromosome; Piperazines; Pyrimidines | 2007 |
New therapeutic approaches and prognostic factors in chronic myeloid leukemia.
Topics: Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genomic Instability; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Pyrimidines | 2008 |
1 trial(s) available for imatinib mesylate and Genome Instability
| Article | Year |
|---|---|
Random aneuploidy in CML patients at diagnosis and under imatinib treatment.
Topics: Adult; Aged; Aneuploidy; Antineoplastic Agents; Benzamides; Female; Genomic Instability; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Tumor Cells, Cultured | 2006 |
10 other study(ies) available for imatinib mesylate and Genome Instability
| Article | Year |
|---|---|
Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells.
Topics: Animals; Antineoplastic Agents; Benzamides; Cells, Cultured; DNA Damage; Drug Resistance, Neoplasm; Genomic Instability; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Transgenic; Neoplastic Stem Cells; Oxidative Stress; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reactive Oxygen Species | 2013 |
Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blast Crisis; Cell Division; Cell Line, Tumor; Cytostatic Agents; Gene Expression Regulation, Leukemic; Genes, abl; Genes, Tumor Suppressor; Genomic Instability; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Experimental; Leukemia, Myeloid, Chronic-Phase; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Proteins; Neoplastic Stem Cells; Oncogene Proteins v-abl; Oncogene Proteins, Fusion; Oxidative Stress; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyridazines; Tumor Suppressor Proteins | 2016 |
Assessment of the genotoxicity of the tyrosine kinase inhibitor imatinib mesylate in cultured fish and human cells.
Topics: Animals; Cell Line, Tumor; Cells, Cultured; DNA Damage; Genomic Instability; Humans; Imatinib Mesylate; Mutagenicity Tests; Protein-Tyrosine Kinases; Zebrafish | 2017 |
Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Disease Progression; Female; Genomic Instability; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Risk Factors; Thiazoles; Translocation, Genetic | 2010 |
MYC in chronic myeloid leukemia: induction of aberrant DNA synthesis and association with poor response to imatinib.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Disease Progression; DNA Replication; Fusion Proteins, bcr-abl; Genomic Instability; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-myc; Pyrimidines | 2011 |
Trisomy 8 in Philadelphia chromosome negative cell preceding the evolution of a Philadelphia chromosome positive clone with the same additional change during imatinib treatment: revisiting the role of genetic instability in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Chromatography, High Pressure Liquid; Chromosomes, Human, Pair 8; Clone Cells; Dasatinib; DNA Mutational Analysis; Genomic Instability; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Molecular Targeted Therapy; Philadelphia Chromosome; Piperazines; Preleukemia; Protein Kinase Inhibitors; Pyrimidines; Real-Time Polymerase Chain Reaction; Selection, Genetic; Thiazoles; Trisomy | 2012 |
Chronic myeloid leukemia stem cells display alterations in expression of genes involved in oxidative phosphorylation.
Topics: Adenosine Triphosphate; Analysis of Variance; Benzamides; Drug Resistance, Neoplasm; Electron Transport Chain Complex Proteins; Fusion Proteins, bcr-abl; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Genomic Instability; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Mutation; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Oxidative Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reactive Oxygen Species | 2012 |
The proteolytic activity of separase in BCR-ABL-positive cells is increased by imatinib.
Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Cell Cycle Proteins; Cyclin B1; Drug Resistance, Neoplasm; Endopeptidases; Fusion Proteins, bcr-abl; Genomic Instability; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Phosphorylation; Piperazines; Protein Phosphatase 2; Proteolysis; Pyrimidines; Securin; Separase; U937 Cells | 2012 |
Pathobiology of lymphoid and myeloid blast crisis and management issues.
Topics: Algorithms; Antineoplastic Agents; Benzamides; Blast Crisis; Fusion Proteins, bcr-abl; Genes, abl; Genomic Instability; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2005 |
Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.
Topics: Benzamides; Colony-Forming Units Assay; DNA Mutational Analysis; DNA Primers; Genes, abl; Genomic Instability; Humans; Imatinib Mesylate; Immunomagnetic Separation; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Stem Cells; Tumor Cells, Cultured | 2007 |